Every material Form 8-K IQVIA has filed with the SEC since February 06, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IQVIA reported third-quarter 2026 revenue of $4,428 million, up 8.0%, and Adjusted Diluted EPS of $3.34, up 11.3% year-over-year. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS, which is the key development for shareholders. The filing also discloses a backlog adjustment of approximately $2.1 billion tied to a review of inactive trials, which the company says does not affect 2026 guidance.
Q3 revenue $4,428 million, up 8.0% reported and 8.6% at constant currency; GAAP diluted EPS $2.10 versus $1.93 a year earlier
Full-year 2026 revenue guidance raised to $17,350 million to $17,500 million; Adjusted EBITDA to $4,025 million to $4,055 million
Full-year 2026 Adjusted Diluted EPS guidance raised to $12.90 to $13.00
Backlog adjusted by approximately $2.1 billion after review of inactive trials; R&DS contracted backlog stood at $32.6 billion as of September 30, 2026
IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings, completed a $2 billion offering of 6.375% senior notes maturing March 15, 2034. Proceeds will redeem the issuer's 5.000% notes due 2026, repay part of its revolving credit facility and cover offering fees. The deal refinances existing debt and adds new long-term borrowing, which shareholders may weigh against the company's debt load.
Gross proceeds of $2,000,000,000 from 6.375% senior unsecured notes due March 15, 2034
Proceeds to redeem in full the Senior 5.000% Notes due 2026 and repay part of the revolving credit facility
Interest payable semi-annually on March 15 and September 15, starting March 15, 2027
Issuer may redeem before September 15, 2029 subject to a make-whole premium
IQVIA reported second-quarter 2026 revenue of $4,368 million, up 8.7% year-over-year, and adjusted diluted earnings per share of $3.15, up 12.1%. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS, though GAAP net income and GAAP diluted EPS were slightly lower than a year earlier.
Revenue was $4,368 million, up 8.7%; R&D Solutions net new bookings were $3.15 billion, up 19%, with a 1.22x book-to-bill ratio.
GAAP diluted EPS was $1.53 versus $1.54 a year earlier; GAAP net income attributable to IQVIA was $256 million versus $266 million.
Full-year 2026 revenue guidance was raised to $17,275 million–$17,475 million; Adjusted EBITDA to $4,000 million–$4,050 million; Adjusted Diluted EPS to $12.80–$13.00.
The company repurchased $398 million of common stock in the second quarter and had $2,819 million of authorization remaining as of June 30, 2026.
IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings, issued €950 million in senior notes maturing June 15, 2033, with proceeds used to refinance existing debt and pay offering fees. The notes add new unsecured debt to the company's obligations, though the filing does not describe the effect on total leverage.
Issued €950,000,000 in gross proceeds of 4.625% senior notes due June 15, 2033, on June 11, 2026
Interest payable semi-annually on June 15 and December 15, beginning December 15, 2026
Proceeds to refinance certain existing indebtedness of the Issuer and pay offering fees and expenses
Optional redemption before June 15, 2029 subject to a make-whole premium; premium steps down from 2.313% to 0.000% thereafter
IQVIA reported first-quarter 2026 revenue of $4,151 million, up 8.4% from a year earlier, and GAAP diluted EPS of $1.61 versus $1.40. The company raised its full-year 2026 adjusted diluted EPS guidance to $12.65-$12.95 while reaffirming its revenue and Adjusted EBITDA guidance, and it repurchased $552 million of its stock during the quarter.
Q1 2026 revenue $4,151 million, up 8.4% reported and 6.0% at constant currency; GAAP net income $274 million versus $249 million a year earlier
Adjusted diluted EPS $2.90, up 7.4% year-over-year; GAAP diluted EPS $1.61 versus $1.40
Full-year 2026 adjusted diluted EPS guidance raised to $12.65-$12.95; revenue guidance of $17,150-$17,350 million and Adjusted EBITDA guidance of $3,975-$4,025 million reaffirmed
Free cash flow $491 million, up 15%; $552 million of common stock repurchased in the quarter, with $1,217 million of authorization remaining as of March 31, 2026
At its April 23, 2026 annual meeting, IQVIA stockholders approved the 2026 Incentive and Stock Award Plan, which replaces the 2017 Plan and takes effect immediately. Stockholders also elected nine directors and voted on other proposals, and the separate Chairman and CEO roles proposal was not approved. The equity plan sets the terms under which future stock-based awards can be granted to employees.
Plan approval: 96,987,612 votes for and 51,006,455 against
Plan replaces the 2017 Incentive and Stock Award Plan and assumes any shares remaining under it
Nine directors elected to one-year terms by majority vote, including Ari Bousbib and Colleen A. Goggins
Separate Chairman and CEO roles proposal: 36,717,802 for and 111,154,252 against
IQVIA reported fourth-quarter 2025 revenue of $4,364 million, up 10.3% from a year earlier, with GAAP diluted EPS of $2.99 and adjusted diluted EPS of $3.42. The company also issued full-year 2026 guidance of $17,150 million to $17,350 million in revenue and $12.55 to $12.85 in adjusted diluted EPS, and said it will recast its segments beginning with the first-quarter 2026 Form 10-Q. For shareholders, the quarter showed revenue and EPS growth, while full-year GAAP net income was slightly lower.
Q4 2025 revenue $4,364 million, up 10.3%; GAAP diluted EPS $2.99, up 23.6%; adjusted diluted EPS $3.42, up 9.6%
Full-year 2025 revenue $16,310 million, up 5.9%; GAAP net income $1,360 million, down 0.9%
2026 guidance: revenue $17,150 million to $17,350 million; adjusted EBITDA $3,975 million to $4,025 million
Share repurchases of $1,244 million in 2025; $1,769 million authorization remaining as of December 31, 2025
IQVIA Holdings entered into Amendment No. 5 to its Fifth Amended and Restated Credit Agreement on December 9, 2025. The amendment refinances existing term and revolving loans into new classes, removes the term SOFR credit spread adjustment on U.S. dollar term A and revolving loans to lower their interest rate, and releases the Swiss Subsidiary Borrower and the Japanese Borrower from their obligations under the agreement. The filing does not state dollar amounts, so the size of the financial effect is not disclosed.
Agreement amended on December 9, 2025, covering the Fifth Amended and Restated Credit Agreement
Term A-1, Term A-2 and Term A Euro loans, plus U.S., Japanese and Swiss/Multicurrency revolving commitments, refinanced into new classes
Term SOFR credit spread adjustment eliminated on U.S. dollar term A and revolving loans, lowering their interest rate
Swiss Subsidiary Borrower and Japanese Borrower released from all borrower obligations
IQVIA's board appointed Dr. William G. Kaelin Jr. as a director effective November 5, 2025, and the board determined he is independent under New York Stock Exchange rules. The filing discloses a board addition only and contains no financial results or guidance.
Dr. William G. Kaelin Jr. appointed to the board on November 5, 2025
Board determined Dr. Kaelin meets the NYSE definition of independent director
He will receive non-employee director compensation and sign the standard indemnification agreement
Dr. Kaelin shared the 2019 Nobel Prize in Physiology or Medicine and serves on the board of Eli Lilly and Company
IQVIA reported third-quarter 2025 results on October 28, 2025, with revenue of $4.1 billion, up 5.2% from a year earlier, and GAAP net income of $331 million, up from $285 million. The company reaffirmed the midpoint of its full-year 2025 guidance and narrowed its revenue, Adjusted EBITDA and Adjusted diluted EPS ranges. Adjusted EBITDA rose 1.1% to $949 million, slower than revenue growth, but the headline revenue and per-share measures improved.
Q3 revenue was $4,100 million, up 5.2% on a reported basis from $3,896 million in Q3 2024.
GAAP diluted EPS was $1.93, up from $1.55; Adjusted diluted EPS was $3.00, up from $2.84.
Full-year 2025 guidance: revenue $16,150 million to $16,250 million; Adjusted EBITDA $3,775 million to $3,800 million; Adjusted diluted EPS $11.85 to $11.95.
Free cash flow was $772 million, up 35% year-over-year.
IQVIA said Michael J. Fedock, currently Senior Vice President of Financial Planning and Analysis, will become Executive Vice President and Chief Financial Officer effective February 28, 2026. Ronald E. Bruehlman will retire as CFO on that date and become Senior Advisor to CEO Ari Bousbib, which the company said is part of a previously announced CFO succession plan.
Michael J. Fedock, age 50, succeeds Ronald E. Bruehlman as CFO effective February 28, 2026.
Fedock's base salary will rise to $750,000, with an annual cash incentive target of 100% of base salary.
Bruehlman will move to Senior Advisor to CEO Ari Bousbib, effective the same date.
The filing does not report any financial results or guidance changes.
IQVIA reported second-quarter 2025 revenue of $4,017 million, up 5.3% from a year earlier, and adjusted diluted earnings per share of $2.81, up from $2.64. GAAP net income fell to $266 million from $363 million, and the company issued updated full-year 2025 guidance of $16.1 billion to $16.3 billion in revenue and $11.75 to $12.05 in adjusted diluted EPS. The filing does not show the prior guidance, so the direction of the guidance change cannot be determined from this document.
Q2 revenue of $4,017 million, up 5.3% reported and 3.6% at constant currency
GAAP diluted EPS of $1.54 versus $1.97 a year earlier; adjusted diluted EPS of $2.81 versus $2.64
Full-year 2025 guidance: revenue $16,100 million to $16,300 million; adjusted diluted EPS $11.75 to $12.05
Repurchased $607 million of common stock in Q2; $1,981 million of authorization remained as of June 30, 2025
IQVIA's wholly owned subsidiary IQVIA Inc. completed a $2.0 billion sale of 6.250% senior unsecured notes maturing June 1, 2032. Proceeds will mainly repay borrowings under its revolving credit facility, with the rest covering offering fees and general corporate purposes, so the filing shows a refinancing of existing debt rather than new spending.
Gross proceeds of $2,000,000,000 from 6.250% senior notes due June 1, 2032
Interest payable semi-annually on June 1 and December 1, starting December 1, 2025
Proceeds to repay existing revolving credit facility borrowings and pay offering fees and expenses
Issued under an indenture dated June 4, 2025, with U.S. Bank Trust Company, National Association, as trustee
IQVIA reported first-quarter 2025 results on May 6, 2025, with revenue up 2.5% to $3,829 million, while GAAP net income fell to $249 million from $288 million a year earlier. The company raised its full-year 2025 revenue guidance by $275 million on more favorable foreign currency rates and reaffirmed its Adjusted EBITDA and Adjusted Diluted EPS guidance, so shareholders see higher sales and adjusted profit alongside lower GAAP earnings.
Revenue of $3,829 million, up 2.5% reported and 3.5% at constant currency from $3,737 million
GAAP diluted EPS of $1.40 versus $1.56, and GAAP net income of $249 million versus $288 million
Adjusted Diluted EPS of $2.70, up 6.3%, and Adjusted EBITDA of $883 million, up 2.4%
Full-year 2025 revenue guidance raised to $16,000 million to $16,400 million; profit guidance reaffirmed
IQVIA Holdings entered into Amendment No. 4 to its Fifth Amended and Restated Credit Agreement on March 10, 2025. The amendment creates new term B dollar loans used to refinance Term B-4 Dollar Loans at a lower margin and to repay Term B-2 Euro Loans in full. The filing does not state the loan amounts, so the size of the change in borrowing costs cannot be determined from it.
Term B-4 Dollar Loans refinanced; margin cut from SOFR plus 2.00% to SOFR plus 1.75% per annum
Term B-2 Euro Loans to be repaid in full under the amendment
Amendment dated March 10, 2025; administrative agent is Bank of America, N.A.
Filing does not disclose principal amounts of the new or repaid loans
IQVIA reported fourth-quarter 2024 revenue of $3,958 million, up 2.3% on a reported basis, and adjusted diluted EPS of $3.12, up 9.9%. GAAP diluted EPS fell 4.7% to $2.42, and the company reaffirmed its 2025 outlook while raising its share repurchase authorization by $2.0 billion to $3.013 billion.
Q4 2024 revenue was $3,958 million, up 2.3% reported and 3.0% at constant currency; full-year revenue was $15,405 million, up 2.8%.
Q4 GAAP net income was $437 million, down 6.8%; adjusted diluted EPS was $3.12, up 9.9%.
2025 guidance reaffirmed: revenue of $15,725 million to $16,125 million and adjusted diluted EPS of $11.70 to $12.10.
Board increased share repurchase authorization by $2,000 million on February 5, 2025; full-year 2024 repurchases totaled $1,350 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IQVIA filing is on SEC EDGAR ↗. 8-K briefs of other companies →